Studies of the Effects of Perfluorocarbon Emulsions on Platelet Number and Function in Models of Critical Battlefield Injury
Abstract
Perfluorocarbon emulsions (PFCs) can treat traumatic injuries (traumatic brain injury (TBI), hemorrhagic shock and burns) by enhanced delivery of oxygen. A class-based side effect of PFC (day 2-5 after infusion in 30-50%) may be thrombocytopenia (TCYP). The mechanism is inadequately investigated. The US Food and Drug Administration (FDA) requests investigation of the phenomenon to exclude platelet inflammatory/embolic safety risks. In phase one of the study, the results showed that the sheeps platelet number and activation were not significantly changed after PFC infusion. In 2014, PFC intravenous infusion as a part of resuscitation fluid was used in hemorrhagic sheep (PFC: oxygent, n=6; saline: n=7; surgical control: n=6). The initial results showed that the sheeps platelet count and fibrinogen level were not significantly reduced after PFC infusion compared with non-PFC controls for the 7 survival days. Platelet contractile force (PCF, Platelet activator) also showed no significant reduction compared with control groups (saline and surgical control). Platelet morphological observation corresponds with function assays. There are no significant percentage changes in neutrophils and monocytes after PFC infusion. Therefore, intravenous infusion of Oxygent (PFC) in hemorrhagic shock sheep did not cause massive or severe coagulopathy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2015
- Accession Number
- AD1024728
Entities
People
- Bruce D Spiess
Organizations
- Virginia Commonwealth University